Neovista sees $18M to treat eye disorders
Neovista, a Fremont, Calif.-based biotech company specializing in eye diseases, says it raised $18 million in a fourth round of funding to commercialize its new device. The money came from Accuitive Medical Ventures, Carlyle Group, Essex Woodlands Health Ventures, MPM Capital, SV Life Sciences and Versant Ventures.
The company says the money should be enough to see the device through to approval by the Food and Drug Administration in 2010. The product has already been cleared… Continue Reading
NeoVista, a co. targeting age-related macular degeneration, raises $41M
NeoVista, a Fremont ophthalmic device company focusing on the treatment of wet age-related macular degeneration, said it has raised a third $41 million round of venture financing.
The company is in the early stages of testing its technology, and it won’t hit the market until around 2010 at the earliest. Separately, VentureWire reports a comment from the company’s VP of marketing that the company had received interest from a company about a possible acquisition.
New investors Essex… Continue Reading
NeoVista, a radiation treatment device maker, to raise $26M
Radiation treatment device maker NeoVista wants to raise up to $26 million in a Series B financing in time to begin pivotal trials of its device for treating an age-related degenerative eye disease, according to VentureWire (sub required).
There are securities regulations that discourage companies from making open public pitches for money, so we’re not sure how legally kosher this for a company to broadcast its precise plans to the world this way (regulators fear that… Continue Reading